Histogen Inc. (HSTO)

$2.3199

+0.02 (+0.87%)
Rating:
Recommendation:
-
Symbol HSTO
Price $2.3199
Beta -0.173
Volume Avg. 0.16M
Market Cap 5.794M
Shares () -
52 Week Range 2.06-22.2
1y Target Est -
DCF Unlevered HSTO DCF ->
DCF Levered HSTO LDCF ->
ROE -51.84% Strong Sell
ROA -36.23% Strong Sell
Operating Margin -
Debt / Equity 57.26% Buy
P/E -
P/B 5.60 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest HSTO news


Mr. Richard W. Pascoe
Healthcare
Biotechnology
NASDAQ Capital Market

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.